OSTEOSARCOMA

This study tests a new drug called HS-20093 against a standard chemotherapy combination for people with osteosarcoma (bone cancer) that has not responded to at least two prior treatments. About 117 participants aged 12 and older will be randomly assigned to receive either HS-2009…

This early-phase study tests a two-part treatment for osteosarcoma that has not responded to standard therapy or has returned. First, participants receive a modified version of their own immune cells (CAR T cells) that are designed to recognize a special marker. Then, they get in…

This early-phase study tests an experimental drug called CLR 131 in children, adolescents, and young adults (ages up to 30) with certain cancers that have come back or not responded to standard treatments. The cancers include solid tumors (like neuroblastoma and sarcomas), lympho…

This study tests two drugs—nivolumab alone or with azacitidine—in people whose osteosarcoma (a type of bone cancer) has come back and can be surgically removed. The goal is to see if the treatment is safe and helps keep the cancer from returning after surgery. About 21 adults and…

This study tests a combination of two drugs (regorafenib and nivolumab) in people with osteosarcoma, a type of bone cancer, that has returned or not responded to prior treatment. The goal is to see if this combination can stop the cancer from growing for at least 4 months longer …

This study tests whether combining two drugs, olaparib and ceralasertib, can help control osteosarcoma that has come back or not responded to treatment. About 63 people aged 12 to 40 with this rare bone cancer will take part. The goal is to see if the combination can stop the can…

This early-phase study tests a new treatment for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein c…

This study tests a daily pill called cabozantinib in children and young adults (up to age 30) with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. The drug works by blocking signals that help tumors grow and form blood vessel…

This study tests a drug called regorafenib in 30 teens (ages 9-21) with Ewing sarcoma or osteosarcoma that has come back or not responded to standard therapy. The goal is to see if the drug can improve how long they live without the cancer growing, while also checking for side ef…

This study tests a drug called DS-8201a in people aged 12 to 39 with a type of bone cancer (osteosarcoma) that has come back and has a specific marker (HER2+). The drug combines an antibody that seeks out HER2+ cells with a chemotherapy agent to kill them. The goal is to see if i…

This early-phase study tests a new treatment for advanced osteosarcoma and neuroblastoma that has not responded to standard therapies. The approach uses a patient's own immune cells (T cells) that are genetically modified to recognize and attack cancer cells carrying a protein ca…

This early-phase study tests a personalized cell therapy for children and young adults (ages 1–30) whose solid tumors have come back or not responded to standard treatment. Researchers take a patient's own immune T cells, modify them to recognize and attack cancer cells that carr…

This study tests two immunotherapy drugs, cobolimab and dostarlimab, together in children and young adults (up to age 21) with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the combination can shrink tumors. The …

This trial tests whether adding the drug mifamurtide to standard chemotherapy after surgery helps people with high-risk osteosarcoma (a type of bone cancer) live longer without the cancer coming back. The study includes 60 patients aged 2 to 50 with newly diagnosed, aggressive os…

This study looks at whether a special PET scan using a natural amino acid called methionine can help doctors see tumors in children and young adults with cancer. About 500 participants will get the scan to check if it can find tumors at diagnosis and tell the difference between a…

This early study tests whether a drug called glucarpidase can lower the toxic side effects of high-dose methotrexate in adults with osteosarcoma (a type of bone cancer). About 12 participants will receive glucarpidase alongside their chemotherapy to see if it helps clear the chem…

This study looks at tissue samples from 100 people with advanced osteosarcoma to see how often the MTAP protein is missing. Researchers want to find out if MTAP loss is linked to cancer spread and immune system activity. No new treatments are given; the goal is to gather informat…

This study follows 500 adults aged 18-65 who finished chemotherapy for certain cancers and are in remission. Over 5 years, researchers will check for 19 possible late side effects like heart problems, memory issues, and fatigue. The goal is to catch these problems early and impro…

This study looks at tumor samples from people with bone cancer (osteosarcoma) to understand why some tumors don't respond to chemotherapy. Researchers will test these samples in the lab and also study blood markers. The goal is to learn more about drug resistance, not to test a n…